David Friedman MD in Elkin, North Carolina

Medical School: Tufts University School Of Medicine
Graduation Year: 1980
The Primary Medical Specialty for David Friedman MD is listed as: General Surgery
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 44
PAC (PECOS ID)#: 6800795865
NPI #: 1427054683
NPI Created On: 06/22/2005
NPI Last Updated Listed as: 01/14/2022
Primary Taxonomy Code: 208600000X
License Number:
8245
Listed Gender: Male

---

Forms of insurance accepted by include, but are not limited to:

• Blue Cross Blue Shield
• Molina Healthcare of New Mexico, Inc.
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English, Spanish.

---

Services and Procedures include:

1. Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope
2. Diagnostic examination of large bowel using an endoscope
3. Biopsy of large bowel using an endoscope
4. Removal of polyps or growths in large bowel using an endoscope
5. Removal of polyps or growths of large bowel using an endoscope
6. Removal of gallbladder using an endoscope
7. New patient office or other outpatient visit, typically 20 minutes
8. New patient office or other outpatient visit, typically 30 minutes
9. New patient office or other outpatient visit, typically 45 minutes
10. Established patient office or other outpatient visit, typically 10 minutes
11. Established patient office or other outpatient visit, typically 15 minutes
12. Established patient office or other outpatient, visit typically 25 minutes
13. Initial hospital inpatient care, typically 30 minutes per day
14. Subsequent hospital inpatient care, typically 15 minutes per day
15. Subsequent hospital inpatient care, typically 25 minutes per day
16. Colorectal cancer screening; colonoscopy on individual at high risk
17. Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk

They took part in the Medicare Physician Quality Reporting System (PQRS).

They took part in the Million Hearts Initiative, which was deigned to improve cardiac outcomes.